Evidence map›Paper›PMID 38645124›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Optimizing Antidepressant Efficacy: Generalizable Multimodal Neuroimaging Biomarkers for Prediction of Treatment Response.

Xiaoyu Tong, Kanhao Zhao, Gregory A Fonzo, Hua Xie, Nancy B Carlisle, Corey J Keller, Desmond J Oathes, Yvette Sheline, Charles B Nemeroff, Madhukar Trivedi and 2 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiaoyu TongDepartment of Bioengineering, Lehigh University, Bethlehem, PA, USA.
Kanhao ZhaoDepartment of Bioengineering, Lehigh University, Bethlehem, PA, USA.
Gregory A FonzoCenter for Psychedelic Research and Therapy, Department of Psychiatry and Behavioral Sciences, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.
Hua XieCenter for Neuroscience Research, Children's National Hospital, Washington, DC, USA.
Nancy B CarlisleDepartment of Psychology, Lehigh University, Bethlehem, PA, USA.
Corey J KellerWu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0003-0529-3490
Desmond J OathesCenter for Brain Imaging and Stimulation, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID 0000-0001-7346-2669
Yvette ShelineCenter for Neuromodulation in Depression and Stress, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Charles B NemeroffCenter for Psychedelic Research and Therapy, Department of Psychiatry and Behavioral Sciences, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.
Madhukar TrivediThe University of Texas Southwestern Medical Center, Department of Psychiatry, Center for Depression Research and Clinical Care, Dallas, TX, USA.
Amit EtkinDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Yu ZhangDepartment of Bioengineering, Lehigh University, Bethlehem, PA, USA.

Funding

1/2 Neurodevelopmental and clinical trajectories of youth at risk for bipolar I disorderR01MH125886 · NIMH · UNIVERSITY OF TEXAS AT AUSTIN · PI ALMEIDA, JORGE R C, STRAKOWSKI, STEPHEN M · 2021 to 2025
$4.3M
Establishing Multimodal Brain Biomarkers Using Data-driven Analyticsfor Treatment Selection in DepressionR01MH129694 · NIMH · STANFORD UNIVERSITY · PI Yu Zhang · 2023 to 2026
$2.8M
Computational neuroimaging of reward in post-trauma psychopathologyK23MH114023 · NIMH · UNIVERSITY OF TEXAS AT AUSTIN · PI FONZO, GREGORY · 2018 to 2022
$957k
Assess Neural Circuits and Subtypes Underlying Dimensions of Neuropsychiatric Symptoms in Alzheimer's DiseaseR21AG080425 · NIA · LEHIGH UNIVERSITY · PI ZHANG, YU · 2023 to 2024
$426k
Identifying Transdiagnostic Functional Connectivity Biomarkers for Cognitive Health and PsychopathologyR21MH130956 · NIMH · LEHIGH UNIVERSITY · PI BERDICHEVSKY, YEVGENY · 2023 to 2024
$409k
NIA NIH HHS R21 AG080425NIMH NIH HHS K23 MH114023NIMH NIH HHS R01 MH125886NIMH NIH HHS R01 MH129694NIMH NIH HHS R21 MH130956
6 · The paper itself

Abstract

Major depressive disorder (MDD) is a common and often severe condition that profoundly diminishes quality of life for individuals across ages and demographic groups. Unfortunately, current antidepressant and psychotherapeutic treatments exhibit limited efficacy and unsatisfactory response rates in a substantial number of patients. The development of effective therapies for MDD is hindered by the insufficiently understood heterogeneity within the disorder and its elusive underlying mechanisms. To address these challenges, we present a target-oriented multimodal fusion framework that robustly predicts antidepressant response by integrating structural and functional connectivity data (sertraline: R

Identifiers

PMID38645124
PMCPMC11030479

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.